KR102663113B1 - Cdk9 저해제로서의 폴리사이클릭 아미드 유도체 - Google Patents
Cdk9 저해제로서의 폴리사이클릭 아미드 유도체 Download PDFInfo
- Publication number
- KR102663113B1 KR102663113B1 KR1020187002262A KR20187002262A KR102663113B1 KR 102663113 B1 KR102663113 B1 KR 102663113B1 KR 1020187002262 A KR1020187002262 A KR 1020187002262A KR 20187002262 A KR20187002262 A KR 20187002262A KR 102663113 B1 KR102663113 B1 KR 102663113B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyridin
- chloro
- cyclohexanecarboxamide
- acetamido
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
- Polyesters Or Polycarbonates (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| US62/185,852 | 2015-06-29 | ||
| PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180021830A KR20180021830A (ko) | 2018-03-05 |
| KR102663113B1 true KR102663113B1 (ko) | 2024-05-02 |
Family
ID=56292699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187002262A Active KR102663113B1 (ko) | 2015-06-29 | 2016-06-27 | Cdk9 저해제로서의 폴리사이클릭 아미드 유도체 |
Country Status (38)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020005039A2 (pt) | 2017-09-25 | 2020-09-15 | Astrazeneca Ab | combinação de um inibidor de btk e um inibidor de cdk9 para tratar câncer |
| EP3694506B1 (en) * | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| WO2020259556A1 (zh) * | 2019-06-27 | 2020-12-30 | 南京明德新药研发有限公司 | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 |
| US20220324830A1 (en) | 2019-09-11 | 2022-10-13 | Prelude Therapeutics, Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| AU2020401999B2 (en) * | 2019-12-09 | 2024-01-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| WO2021227906A1 (zh) * | 2020-05-12 | 2021-11-18 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 |
| JP7406008B2 (ja) * | 2020-05-12 | 2023-12-26 | 蘇州阿尓脈生物科技有限公司 | Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途 |
| EP4171654A1 (en) * | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
| EP4194450A4 (en) | 2020-08-07 | 2024-10-30 | Pharmablock Sciences (Nanjing), Inc. | CDK9 INHIBITOR AND USE THEREOF |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381823B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| CN115703738B (zh) * | 2021-08-16 | 2024-06-21 | 中国科学院上海药物研究所 | 含2-芳杂环取代的脲类化合物、其制备方法和用途 |
| US20230279016A1 (en) * | 2021-12-23 | 2023-09-07 | The Katholieke Universiteit Leuven | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD |
| JP2025528223A (ja) | 2022-08-17 | 2025-08-26 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | Ｃｄｋ２及び／又はｃｄｋ９の抑制又は分解用化合物及びこれらの医薬用途 |
| CN117659022A (zh) * | 2022-09-06 | 2024-03-08 | 苏州阿尔脉生物科技有限公司 | 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途 |
| US20240360075A1 (en) * | 2023-04-19 | 2024-10-31 | Alcon Inc. | N-substituted c6 cyclyl carboxamide compounds and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2026024933A1 (en) * | 2024-07-24 | 2026-01-29 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| US20120157433A1 (en) | 2009-09-04 | 2012-06-21 | Pfister Keith B | Heteroaryl Compounds as Kinase Inhibitors |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| US20140275027A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
| WO2014160017A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| US8389521B2 (en) | 2007-04-24 | 2013-03-05 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008129070A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| JP5566880B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体 |
| AU2008309517B2 (en) | 2007-10-12 | 2013-03-14 | Astrazeneca Ab | Inhibitors of protein kinases |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) * | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| CA2789189A1 (en) | 2010-03-10 | 2011-09-15 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| JP2014506878A (ja) * | 2011-01-28 | 2014-03-20 | ノバルティス アーゲー | Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用 |
| RU2627272C2 (ru) * | 2011-10-06 | 2017-08-04 | Байер Интеллектчуал Проперти Гмбх | Гетероциклилпиридинилпиразолы |
| WO2014159999A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Cdk9 kinase inhibitors |
| CA2903538A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
-
2016
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2016-06-27 MY MYPI2017705054A patent/MY201673A/en unknown
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 PH PH1/2017/502334A patent/PH12017502334B1/en unknown
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 SM SM20220005T patent/SMT202200005T1/it unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active Active
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 SM SM20190298T patent/SMT201900298T1/it unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en not_active Ceased
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| US20120157433A1 (en) | 2009-09-04 | 2012-06-21 | Pfister Keith B | Heteroaryl Compounds as Kinase Inhibitors |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2014160017A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| US20140275027A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11352369B2 (en) | Pyridine and pyrimidine derivatives | |
| US8796289B2 (en) | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | |
| TW202246255A (zh) | Ｃｄｋ抑制劑及其使用方法 | |
| TW201938566A (zh) | 囊性纖維化跨膜傳導調節因子之調節劑、醫藥組合物、治療方法及製造該調節劑之方法 | |
| EP3288931B2 (en) | Certain protein kinase inhibitor | |
| CA2864142A1 (en) | Pyridopyrimidinone inhibitors of kinases | |
| JP2016539990A (ja) | ブロモドメイン阻害薬 | |
| JP2019534264A (ja) | ブロモドメイン阻害剤 | |
| EP3609896A1 (en) | Bromodomain inhibitors | |
| HK40014442B (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| HK40014442A (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| HK1250985A1 (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| HK1250985B (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| BR112017027394B1 (pt) | Composto, forma cristalina, composição farmacêutica e uso do mesmo | |
| CA3020378C (en) | Macrocyclic mcl1 inhibitors for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180124 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210625 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230710 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240129 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240429 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240429 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |